Jaguar Health stock surge tops 1,585% after FDA waives 2027 fees

1 day ago 17

Shares of Jaguar Health did something most small-cap biotech stocks never do in a single trading day: they multiplied several times over. The Jaguar Health stock surge unfolded on September 22, 2026, when JAGX shares rocketed as high as 1585.4% during the session, according to Quiver Quantitative’s price-tracking desk, after closing the regular trading day up 1,190.64% at $34.46, based on Benzinga data. The move didn’t stop there — shares kept climbing into after-hours trading, touching $36.25.

Key takeaways

Jaguar Health (JAGX) surged as much as 1585.4% on September 22, 2026, following a 1,190.64% close in the regular session.
The FDA waived 2027 fees for Mytesi and Canalevia-CA1, easing near-term cash pressure tied to those drugs.
Napo received a Prescription Drug User Fee Act waiver for Mytesi for fiscal year 2027.
A 1-for-15 reverse stock split effective September 17, 2026 left Jaguar with roughly 520,088 shares outstanding, a float small enough to fuel extreme volatility.
Jaguar is targeting a mid-2027 NDA filing for crofelemer in microvillus inclusion disease.

Jaguar Health Stock Surges on FDA Fee Waivers and Share Split

The single biggest identifiable catalyst behind the spike was regulatory, not commercial. On September 22, Jaguar announced that it had secured a set of FDA fee waivers tied to two of its approved products, a development that appears to have shifted market sentiment around the company’s cash needs and its broader drug portfolio, according to Quiver Quantitative’s analysis of the move.

FDA Fee Waivers for 2027

According to Benzinga, Napo, the family company of Jaguar Health, announced that the FDA had waived the Prescription Drug User Fee Act fee for Mytesi crofelemer delayed-release tablets for fiscal year 2027, a medication approved to provide symptomatic relief from noninfectious diarrhea in adult HIV/AIDS patients undergoing antiretroviral therapy and marketed in the U.S. by Future Pak, LLC, a Michigan-based pharmaceutical and nutraceutical manufacturer.

Separately, the FDA’s Center for Veterinary Medicine waived fees for Canalevia-CA1, Jaguar’s conditionally approved treatment for chemotherapy-induced diarrhea in dogs, also marketed through Future Pak. Together, the two waivers cover the company’s human and veterinary drug lines heading into 2027, removing a recurring cost that would otherwise have hit the balance sheet.

Impact of 1-for-15 Reverse Stock Split

Layered on top of the regulatory news was a technical setup that made the stock unusually reactive to any positive headline. Jaguar had already carried out a 1-for-15 reverse stock split, effective September 17, 2026, primarily to help the company stay compliant with Nasdaq listing standards. A September 21 regulatory filing showed that, after the split, Jaguar had approximately 520,088 shares outstanding — a remarkably thin float for a Nasdaq-listed company.

That kind of setup can intensify price swings in both directions, and Quiver Quantitative’s analysis pointed to it as a likely amplifier of Tuesday’s rally, noting that the small post-split share count “likely made the stock more prone to sharp momentum swings.” Trading data backs that read: Benzinga reported an RSI of 81.09 for JAGX, a level typically associated with an overbought stock, and Jaguar Health’s market capitalization stood at just $13.73 million even after the surge — evidence of how little liquidity was needed to move the price so dramatically.

Corporate Developments and Regulatory Milestones

Beyond the immediate fee waivers, Jaguar used the same update to reaffirm its longer-term regulatory roadmap, signaling that the company still sees its rare-disease pipeline as the bigger prize.

Mid-2027 NDA Filing Target for Crofelemer

Management said it remains focused on its rare-disease intestinal failure program and is targeting a mid-2027 New Drug Application filing for crofelemer in microvillus inclusion disease, a rare and severe condition. That timeline places the next major regulatory catalyst under a year out, meaning the fee waivers announced this week function more as a near-term financial cushion than as proof the company has cleared its bigger hurdles.

This is where the FDA fee waiver Jaguar news matters most for anyone trying to separate noise from substance: it reduces cost pressure tied to Mytesi and Canalevia-CA1 right now, while the crofelemer program — the asset with the biggest potential upside — is still working toward a filing that won’t happen for several more months.

Investor Activity and Market Volatility

Institutional positioning in JAGX tells a more cautious story than the one-day chart suggests. Quiver Quantitative’s tracking of 13F filings shows that three institutional investors added shares of JAGX in their most recent quarter, while ten decreased their positions — a lopsided ratio that points to broad institutional retreat even as the stock briefly spiked.

Institutional Investor Shareholding Changes

Several of the largest moves came in the first half of 2026, well before Tuesday’s rally. DRW Securities, LLC exited its position entirely in the first quarter, removing 17,823 shares for an estimated $6,603. XTX Topco Ltd also went to zero, cutting 12,451 shares worth an estimated $4,613. In the second quarter, Geode Capital Management, LLC eliminated 3,146 shares valued at roughly $9,438, SBI Securities Co., Ltd. cut 96.7% of its stake, and HRT Financial LP closed out its position completely.

Not every institution was selling, though. Tower Research Capital LLC added 1,094 shares — a 1,657.6% increase — worth an estimated $3,282 in the second quarter, and UBS Group AG added 774 shares, up 24%, for about $2,322. Those additions were modest in dollar terms but stand out against a backdrop of otherwise heavy institutional exits tracked through institutional investor JAGX filings.

Effects of Small Share Float on Stock Volatility

The combination of a shrunken share count and thin institutional ownership helps explain why a single day’s news could move the stock by four figures in percentage terms. With only about 520,088 shares outstanding after the reverse split, even relatively small pockets of buying volume can produce outsized percentage moves — and that same structure works in reverse when sentiment turns. Repeated volatility pauses during Tuesday’s session, noted in trading data cited by Quiver Quantitative, reflect exactly that dynamic playing out in real time.

Jaguar Health stock has fallen 96.77% over the past 12 months and was trading close to its 52-week low of $2.37 before this week’s move, against a 52-week high of $1,280.95, according to Benzinga data reported through TradingView. That context matters: even after a surge measured in the thousands of percent, the stock remains a fraction of where it traded a year earlier, and Benzinga’s Edge Stock Rankings still show a negative price trend across all time frames.

FAQ

What caused Jaguar Health’s stock to surge over 1500% on September 22, 2026?

The stock surge was primarily driven by the FDA granting fee waivers for Jaguar’s drugs Mytesi and Canalevia-CA1, alongside a recent 1-for-15 reverse stock split that reduced shares outstanding and increased volatility.

What FDA fee waivers did Jaguar Health and related companies receive for 2027?

Jaguar Health received FDA fee waivers for Mytesi and Canalevia-CA1 for 2027, and Napo received a Prescription Drug User Fee Act waiver for Mytesi.

What is the significance of Jaguar Health’s 1-for-15 reverse stock split?

The reverse stock split, effective September 17, 2026, reduced the number of shares outstanding to about 520,088, increasing price volatility and helping Nasdaq listing compliance.